analyz
strategi
use
stockpil
antivir
drug
context
futur
influenza
pandem
estim
costbenefit
ratio
current
stockpil
oseltamivir
appear
costsav
economi
sever
treatment
strategi
includ
therapeut
treatment
patient
postexposur
prophylact
treatment
patient
close
contact
widespread
epidem
highli
pathogen
avian
influenza
emerg
east
asia
continu
today
epidem
grow
probabl
virul
viru
acquir
genet
trait
increas
persontoperson
transmiss
potenti
set
stage
next
global
influenza
pandem
next
pandem
associ
major
advers
health
econom
outcom
estim
cost
reach
us
billion
unit
state
alon
world
health
organ
recent
encourag
health
author
consid
stockpil
antivir
drug
anticip
pandem
howev
costbenefit
stockpil
yet
assess
optim
strategi
antivir
use
still
debat
isra
ministri
health
appoint
work
group
address
nation
prepar
influenza
pandem
set
identifi
strategi
use
antivir
drug
oseltamivir
contain
pandem
construct
mathemat
model
apprais
cost
benefit
strategi
term
healthrel
econom
outcom
estim
healthrel
impact
pandem
influenza
isra
popul
use
rate
ill
physician
visit
hospit
death
deriv
previou
pandem
accord
meltzer
et
al
cost
relat
outcom
calcul
data
provid
major
isra
healthcar
organ
isra
central
bureau
statist
calcul
direct
cost
healthcar
system
overal
cost
economi
latter
includ
valu
lost
workday
potenti
valu
lost
live
point
estim
variabl
use
basecas
model
detail
tabl
onlin
appendix
avail
http
accord
basecas
assumpt
pandem
would
result
estim
patient
isra
popul
physician
visit
hospit
death
lost
workday
outcom
would
result
excess
million
healthrel
cost
overal
cost
economi
million
isra
gross
domest
product
defin
strategi
use
antivir
drug
pandem
therapeut
use
longterm
preexposur
prophylaxi
shortterm
postexposur
prophylaxi
close
contact
influenza
patient
index
patient
treatment
first
strategi
could
target
either
entir
popul
high
risk
complic
efficaci
therapeut
treatment
base
current
avail
evid
regard
epidem
influenza
onlin
appendix
systemat
review
metaanalysi
use
estim
efficaci
preexposur
prophylaxi
expect
efficaci
postexposur
prophylaxi
number
person
treat
strategi
estim
use
result
recent
publish
stochast
simul
model
impact
strategi
healthrel
outcom
analyz
spreadsheet
model
use
formula
summar
onlin
appendix
avail
http
briefli
econom
benefit
strategi
calcul
multipli
reduct
advers
outcom
estim
econom
valu
cost
strategi
calcul
multipli
estim
number
treat
person
discount
cost
singl
antivir
cours
oseltamivir
select
drug
choic
daili
dosag
mg
prophylaxi
mg
treatment
oseltamivir
stockpil
cost
calcul
price
quot
march
manufactur
repres
israel
uncapsul
watersolubl
bulk
activ
powder
shelf
life
compar
econom
outcom
strategi
nonintervent
estim
stockpil
cost
calcul
costbenefit
ratio
base
histor
incid
influenza
pandem
last
centuri
adjust
costbenefit
outcom
conserv
estim
probabl
pandem
everi
year
appli
wide
rang
estim
sensit
analys
onlin
appendix
tabl
detail
costbenefit
ratio
compet
strategi
therapeut
treatment
postexposur
prophylaxi
shown
costsav
costbenefit
ratio
sinc
mani
characterist
next
pandem
viral
strain
remain
unknown
model
method
paramet
estim
design
consist
underestim
interventionrel
benefit
thu
yield
minimum
estim
true
costbenefit
ratio
seri
multivari
sensit
analys
use
variabl
rang
detail
tabl
model
prove
robust
even
unfavor
estim
prepandem
stockpil
remain
costsav
long
estim
probabl
pandem
remain
everi
year
consist
advantag
either
therapeut
shortterm
prophylact
use
antivir
drug
could
determin
light
recent
episod
human
infect
avian
influenza
world
health
organ
reiter
call
countri
prepar
next
inevit
possibl
immin
pandem
strainspecif
vaccin
effect
tool
influenza
control
like
avail
earli
stage
pandem
prolong
develop
time
earli
control
measur
employ
altern
option
mainli
judici
use
antivir
drug
drug
like
short
suppli
preemptiv
stockpil
compar
neuraminidas
inhibitor
drug
sever
major
disadvantag
mainli
high
rate
viral
resist
shown
recent
isol
advers
effect
model
suggest
prepandem
stockpil
oseltamivir
costsav
economi
wide
rang
treatment
strategi
stockpil
also
directli
costsav
healthcar
system
oseltamivir
use
limit
treat
patient
high
risk
invest
stockpil
remain
costsav
economi
long
estim
annual
pandem
risk
remain
pandem
everi
year
last
year
least
pandem
record
regardless
recent
event
southeast
asia
present
invest
antivir
agent
expect
yield
substanti
econom
return
per
invest
save
mani
live
favor
costbenefit
ratio
achiev
stockpil
antivir
drug
administ
either
sole
therapeut
measur
shortterm
prophylaxi
expos
contact
strategi
term
ring
prophylaxi
target
prophylaxi
studi
publish
date
use
dynam
mathemat
model
examin
expect
effect
latter
control
measur
popul
level
studi
suggest
strategi
may
significantli
reduc
ill
death
epidemiolog
direct
shortterm
prophylaxi
close
contact
may
requir
antivir
stockpil
consider
larger
necessari
therapeut
treat
patient
model
suggest
invest
may
still
prove
costsav
provid
outbreak
dissemin
pattern
popul
attribut
correl
assum
longini
et
al
onlin
appendix
one
consid
ring
prophylaxi
strategi
risk
strategi
failur
due
earli
antivir
stockpil
deplet
must
consid
postexposur
prophylaxi
confer
suffici
immun
upon
expos
contact
underw
prophylaxi
vaccin
addit
antivir
agent
becom
avail
rapid
consumpt
avail
stock
may
leav
popul
vulner
addit
outbreak
wave
potenti
caus
influx
new
case
probabl
similar
failur
scenario
difficult
assess
includ
analysi
applic
strategi
entir
popul
without
surplu
antivir
reserv
therefor
consid
cautious
monitor
close
studi
aim
elicit
minimum
costbenefit
estim
invest
nation
antivir
stockpil
among
conserv
assumpt
chose
exclud
indirect
cost
prevent
death
ad
would
increas
costbenefit
ratio
onlin
appendix
furthermor
view
recent
event
east
asia
probabl
pandem
probabl
risen
per
year
new
strain
may
prove
pathogen
previou
pandem
strain
model
benefit
therapeut
strategi
omit
benefici
effect
decreas
viral
shed
afford
neuraminidas
inhibitor
lower
secondari
attack
rate
among
untreat
contact
also
ignor
possibl
fulli
implement
prophylact
strategi
might
achiev
full
contain
outbreak
probabl
estim
postexposur
ring
prophylaxi
depend
sever
factor
complianc
delay
treatment
initi
basic
reproduct
number
final
wit
epidem
sever
acut
respiratori
syndrom
sar
econom
consequ
rapidli
dissemin
diseas
extend
well
beyond
direct
cost
healthcar
system
lost
workday
canada
loss
billion
sar
epidem
although
diseas
directli
affect
patient
econom
viewpoint
mitig
pandem
could
prevent
extens
indirect
econom
loss
conclus
studi
must
consid
care
plan
antivir
stockpil
drug
price
expect
chang
substanti
result
contractu
negoti
manufactur
although
result
indic
stockpil
may
remain
costsav
even
drug
cost
tripl
would
case
preprepar
capsul
purchas
powderform
antivir
drug
consider
advantag
term
cost
shelf
life
logist
aspect
prepar
distribut
assess
confirm
feasibl
final
assum
strainspecif
vaccin
would
avail
suffici
quantiti
first
stage
pandem
effort
current
direct
toward
shorten
delay
avail
strainspecif
vaccin
would
like
favor
intervent
antivir
agent
serv
adjunct
treatment
summari
prepandem
stockpil
antivir
drug
expect
prove
costsav
costbenefici
strategi
use
may
involv
treatment
patient
back
adequ
antivir
stockpil
shortterm
postexposur
prophylaxi
close
contact
strategi
consid
plan
stockpil
effort
sever
countri
alreadi
begun
activ
stockpil
effort
suffici
case
allow
antivir
treatment
popul
believ
antivir
stockpil
consid
prudent
invest
may
help
mitig
impend
global
threat
